Similar articles

• Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

  LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. LaRosa JC, et al. N Engl J Med. 2005 Apr 7;352(14):1425-35. doi: 10.1056/NEJMoa050461. Epub 2005 Mar 8. N Engl J Med. 2005. PMID: 15755765 Clinical Trial.
• [To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2005 Aug 18;147(33-34):51. MMW Fortschr Med. 2005. PMID: 16138641 German. No abstract available.
• [Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].

  Mareev VIu, Belenkov IuN, Oganov RG, Barbik-Zhagar B. Mareev VIu, et al. Kardiologiia. 2008;48(11):4-13. Kardiologiia. 2008. PMID: 19076074 Clinical Trial. Russian. No abstract available.
• [LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].

  März W. März W. MMW Fortschr Med. 2003 Dec 11;145(50):46-9. MMW Fortschr Med. 2003. PMID: 14963971 Review. German.
• [Statins in diabetic hyperlipidemia].

  Kirchmair R, Sturm W, Gänzer H, Patsch JR. Kirchmair R, et al. Wien Med Wochenschr. 1999;149(5-6):139-43. Wien Med Wochenschr. 1999. PMID: 10408005 Review. German.